JHVEPhotoOverview Johnson & Johnson (NYSE:JNJ) has always been one of those companies that has a product and service offering so wide and large that JNJ can be considered its own healthcare ETF. Johnson & Johnson operates within the healthcare space with focus on some of the following segments: immunology, infections, neuroscience, and oncology to name a few. In addition, they also operate a segment called MedTech, that provides interventional solutions. With solid financials, a consistent dividend stre ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2.64 per share in its forthcoming report, representing a decline of 1.5% year over year. Revenues are projected to reach $21.38 billion, declining 13.6% from the same quarter last year.The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during th ...

JOHANNESBURG, April 10 (Reuters) - Nigeria's health regulator is recalling a batch of Johnson & Johnson (JNJ.N)New Tab, opens new tab children's cough syrup after finding an unacceptably high level of a potentially fatal toxic substance, it said on Wednesday.Laboratory tests on Benylin Paediatric showed a high level of diethylene glycol, which has been linked to the deaths of dozens of children in Gambia, Uzbekistan and Cameroon since 2022 in one of the world's worst waves of poisoning from oral medication. ...

GERMANY - 2024/02/16: In this photo illustration, a Johnson & Johnson logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor Golovnov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesJohnson & Johnson (NYSE: JNJ) recently announced its plans to acquire Shockwave Medical for $13 billion. Shockwave will help J&J extend its offerings in the cardiovascular intervention market. This acquisition will expand sales growth for J&J’s MedTech segment, which has seen its sa ...

The company is hoping to expand, but is there enough here to attract growth investors?Johnson & Johnson (JNJ 0.46%) has focused more on growth initiatives since spinning off its consumer healthcare business into what is now Kenvue. In 2022, it made a big move with the acquisition of heart pump maker Abiomed for a whopping $16.6 billion. And recently, J&J announced yet another major deal: It is acquiring Shockwave Medical (SWAV 0.54%) for $13.1 billion.What does this mean for the company, and does this move ...

The market expects Johnson & Johnson (JNJ) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be releas ...

Johnson & Johnson (JNJ) ended the recent trading session at $151.59, demonstrating a -0.52% swing from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.04%. On the other hand, the Dow registered a loss of 0.03%, and the technology-centric Nasdaq increased by 0.03%.Shares of the world's biggest maker of health care products have depreciated by 4.47% over the course of the past month, underperforming the Medical sector's loss of 0.6% and the S&P 500's gain of 2.57%.The upcom ...

Key PointsJohnson & Johnson is acquiring Shockwave Medical for $13.1 billion.  The deal will give JNJ access to Shockwave's first-to-market intravascular lithotripsy technology (ILT). The deal could be the jolt that JNJ stock needs to reverse its recent downtrend.  5 stocks we like better than Johnson & JohnsonOn April 5, 2024, Johnson & Johnson NYSE: JNJ announced its intent to acquire Shockwave Medical Inc. NASDAQ: SWAV for $13.1 billion. Under the terms of the proposed deal, JNJ will pay $335 per share, ...